Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Alliance focuses on therapy for cervical high-risk HPV infection, dysplasia
March 31st, 2005
3M and Takeda Pharmaceutical Company Limited (Takeda) announced that the two companies have entered into an exclusive codevelopment and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia. The compound is currently in early stage (phase I) clinical testing. Under the terms of this agreement, 3M and Takeda will share further costs of development. Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain...
Source: Women's Health Weekly (2005-03-31)
|
